Clinical and laboratory diagnosis of autoimmune factor V inhibitors: A single institutional experience

Meera Sridharan, Kara A. Fylling, Aneel Arjun Ashrani, Dong Chen, Ariela L. Marshall, C. Christopher Hook, Laynalee K. Cardel, William L. Nichols, Rajiv K. Pruthi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Coagulation factor V inhibitors (FV-i) may occur in patients with congenital FV deficiency or previously hemostatically normal patients (autoimmune (AI)-FV-i). Most of the published literature is confined to case reports. Objective: Describe clinical and laboratory features of AI-FV-i identified through the Special Coagulation Laboratory at Mayo Clinic, Rochester, Minnesota. Methods: In this retrospective study individuals with FV-i screens performed from January 1999 to February 2017 were identified through the special coagulation laboratory database. Clinical presentation, management, and outcomes were collected for our institutional patients while detailed laboratory data was collected for all tested patients. Results: Of patients with FV-i managed at our institution, 2/8 (25%) patients experienced no bleeding. There was no correlation between inhibitor titers and/or FV activity (FV:C) levels and clinical bleeding. Hemostatic management included fresh frozen plasma, platelet transfusion, activated prothrombin complex concentrates, and recombinant factor VIIa. Only 2 patients received immunomodulatory treatment. FV-i mixing studies with normal pooled plasma (n = 26) demonstrated inhibition on immediate mix but progressive inhibition after 1 h of incubation could not be demonstrated. 71% of platelet neutralization procedures were falsely positive while 59% of DRVVT assays were indeterminate. Conclusion: FV-i demonstrates immediate inhibition on mixing studies; however our limited data does not support a time dependent inhibition. Our clinical cohort confirms the variable clinical phenotype for individuals with FV-i and supports the notion that management of FV-i should be guided by clinical symptoms and not FV:C or FV-i titer.

Original languageEnglish (US)
Pages (from-to)14-21
Number of pages8
JournalThrombosis Research
Volume171
DOIs
StatePublished - Nov 1 2018

Fingerprint

Factor V
Clinical Laboratory Techniques
Hemorrhage
Platelet Transfusion
Hemostatics
Blood Platelets
Retrospective Studies
Databases
Phenotype

Keywords

  • Blood coagulation factor inhibitors
  • Factor V
  • Hemostasis
  • Lupus anticoagulant inhibitor
  • Thrombin

ASJC Scopus subject areas

  • Hematology

Cite this

Clinical and laboratory diagnosis of autoimmune factor V inhibitors : A single institutional experience. / Sridharan, Meera; Fylling, Kara A.; Ashrani, Aneel Arjun; Chen, Dong; Marshall, Ariela L.; Hook, C. Christopher; Cardel, Laynalee K.; Nichols, William L.; Pruthi, Rajiv K.

In: Thrombosis Research, Vol. 171, 01.11.2018, p. 14-21.

Research output: Contribution to journalArticle

Sridharan, M, Fylling, KA, Ashrani, AA, Chen, D, Marshall, AL, Hook, CC, Cardel, LK, Nichols, WL & Pruthi, RK 2018, 'Clinical and laboratory diagnosis of autoimmune factor V inhibitors: A single institutional experience', Thrombosis Research, vol. 171, pp. 14-21. https://doi.org/10.1016/j.thromres.2018.09.044
Sridharan, Meera ; Fylling, Kara A. ; Ashrani, Aneel Arjun ; Chen, Dong ; Marshall, Ariela L. ; Hook, C. Christopher ; Cardel, Laynalee K. ; Nichols, William L. ; Pruthi, Rajiv K. / Clinical and laboratory diagnosis of autoimmune factor V inhibitors : A single institutional experience. In: Thrombosis Research. 2018 ; Vol. 171. pp. 14-21.
@article{8a4b802ed8a24cab86bc915a61f6d628,
title = "Clinical and laboratory diagnosis of autoimmune factor V inhibitors: A single institutional experience",
abstract = "Background: Coagulation factor V inhibitors (FV-i) may occur in patients with congenital FV deficiency or previously hemostatically normal patients (autoimmune (AI)-FV-i). Most of the published literature is confined to case reports. Objective: Describe clinical and laboratory features of AI-FV-i identified through the Special Coagulation Laboratory at Mayo Clinic, Rochester, Minnesota. Methods: In this retrospective study individuals with FV-i screens performed from January 1999 to February 2017 were identified through the special coagulation laboratory database. Clinical presentation, management, and outcomes were collected for our institutional patients while detailed laboratory data was collected for all tested patients. Results: Of patients with FV-i managed at our institution, 2/8 (25{\%}) patients experienced no bleeding. There was no correlation between inhibitor titers and/or FV activity (FV:C) levels and clinical bleeding. Hemostatic management included fresh frozen plasma, platelet transfusion, activated prothrombin complex concentrates, and recombinant factor VIIa. Only 2 patients received immunomodulatory treatment. FV-i mixing studies with normal pooled plasma (n = 26) demonstrated inhibition on immediate mix but progressive inhibition after 1 h of incubation could not be demonstrated. 71{\%} of platelet neutralization procedures were falsely positive while 59{\%} of DRVVT assays were indeterminate. Conclusion: FV-i demonstrates immediate inhibition on mixing studies; however our limited data does not support a time dependent inhibition. Our clinical cohort confirms the variable clinical phenotype for individuals with FV-i and supports the notion that management of FV-i should be guided by clinical symptoms and not FV:C or FV-i titer.",
keywords = "Blood coagulation factor inhibitors, Factor V, Hemostasis, Lupus anticoagulant inhibitor, Thrombin",
author = "Meera Sridharan and Fylling, {Kara A.} and Ashrani, {Aneel Arjun} and Dong Chen and Marshall, {Ariela L.} and Hook, {C. Christopher} and Cardel, {Laynalee K.} and Nichols, {William L.} and Pruthi, {Rajiv K.}",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.thromres.2018.09.044",
language = "English (US)",
volume = "171",
pages = "14--21",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Clinical and laboratory diagnosis of autoimmune factor V inhibitors

T2 - A single institutional experience

AU - Sridharan, Meera

AU - Fylling, Kara A.

AU - Ashrani, Aneel Arjun

AU - Chen, Dong

AU - Marshall, Ariela L.

AU - Hook, C. Christopher

AU - Cardel, Laynalee K.

AU - Nichols, William L.

AU - Pruthi, Rajiv K.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Background: Coagulation factor V inhibitors (FV-i) may occur in patients with congenital FV deficiency or previously hemostatically normal patients (autoimmune (AI)-FV-i). Most of the published literature is confined to case reports. Objective: Describe clinical and laboratory features of AI-FV-i identified through the Special Coagulation Laboratory at Mayo Clinic, Rochester, Minnesota. Methods: In this retrospective study individuals with FV-i screens performed from January 1999 to February 2017 were identified through the special coagulation laboratory database. Clinical presentation, management, and outcomes were collected for our institutional patients while detailed laboratory data was collected for all tested patients. Results: Of patients with FV-i managed at our institution, 2/8 (25%) patients experienced no bleeding. There was no correlation between inhibitor titers and/or FV activity (FV:C) levels and clinical bleeding. Hemostatic management included fresh frozen plasma, platelet transfusion, activated prothrombin complex concentrates, and recombinant factor VIIa. Only 2 patients received immunomodulatory treatment. FV-i mixing studies with normal pooled plasma (n = 26) demonstrated inhibition on immediate mix but progressive inhibition after 1 h of incubation could not be demonstrated. 71% of platelet neutralization procedures were falsely positive while 59% of DRVVT assays were indeterminate. Conclusion: FV-i demonstrates immediate inhibition on mixing studies; however our limited data does not support a time dependent inhibition. Our clinical cohort confirms the variable clinical phenotype for individuals with FV-i and supports the notion that management of FV-i should be guided by clinical symptoms and not FV:C or FV-i titer.

AB - Background: Coagulation factor V inhibitors (FV-i) may occur in patients with congenital FV deficiency or previously hemostatically normal patients (autoimmune (AI)-FV-i). Most of the published literature is confined to case reports. Objective: Describe clinical and laboratory features of AI-FV-i identified through the Special Coagulation Laboratory at Mayo Clinic, Rochester, Minnesota. Methods: In this retrospective study individuals with FV-i screens performed from January 1999 to February 2017 were identified through the special coagulation laboratory database. Clinical presentation, management, and outcomes were collected for our institutional patients while detailed laboratory data was collected for all tested patients. Results: Of patients with FV-i managed at our institution, 2/8 (25%) patients experienced no bleeding. There was no correlation between inhibitor titers and/or FV activity (FV:C) levels and clinical bleeding. Hemostatic management included fresh frozen plasma, platelet transfusion, activated prothrombin complex concentrates, and recombinant factor VIIa. Only 2 patients received immunomodulatory treatment. FV-i mixing studies with normal pooled plasma (n = 26) demonstrated inhibition on immediate mix but progressive inhibition after 1 h of incubation could not be demonstrated. 71% of platelet neutralization procedures were falsely positive while 59% of DRVVT assays were indeterminate. Conclusion: FV-i demonstrates immediate inhibition on mixing studies; however our limited data does not support a time dependent inhibition. Our clinical cohort confirms the variable clinical phenotype for individuals with FV-i and supports the notion that management of FV-i should be guided by clinical symptoms and not FV:C or FV-i titer.

KW - Blood coagulation factor inhibitors

KW - Factor V

KW - Hemostasis

KW - Lupus anticoagulant inhibitor

KW - Thrombin

UR - http://www.scopus.com/inward/record.url?scp=85053289418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053289418&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2018.09.044

DO - 10.1016/j.thromres.2018.09.044

M3 - Article

C2 - 30227314

AN - SCOPUS:85053289418

VL - 171

SP - 14

EP - 21

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

ER -